Close Menu

NEW YORK (GenomeWeb) – The Cellworks Group has announced the results of clinical studies that showed how physicians could leverage the firm's computational biology modeling technology for genomic profiling of tumors and predicting patient response to chemotherapies.

In a prospective clinical study, called iCare 1, the Cellworks artificial intelligence-based technology was 90 percent accurate in predicting the response to standard-of-care treatments in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Holden Thorp is to be the new editor-in-chief of Science and its related journals.

A genetic analysis of salmon scales collected over the course of a century points to a sharp decline in the number of fish returning each year to river in British Columbia, CBC reports.

Adelaide University has suspended the head of an ancient DNA lab as its investigation of workplace bullying continues, Australia's ABC News reports.

In PNAS this week: gene expression profiles of adipocyte subtypes, computational approach for improving plant expressome analysis, and more.